Wound-care company developing continuous topical oxygen therapy (NATROX O2).
| Date | Round | Amount |
|---|---|---|
| Dec 2024 | Series C Cambridge-based Inotec raised 33M USD Series C led by Amadeus Capital Partners to secure US reimbursement for its NATROX O2 wound therapy. | $33M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.